Portal de Periódicos da CAPES

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

2015; Elsevier BV; Volume: 39; Issue: 10 Linguagem: Inglês

10.1016/j.leukres.2015.07.004

1873-5835

Massimo Breccia, Fabio Efficace, Simona Sica, Elisabetta Abruzzese, Michele Cedrone, Diamante Turri, Marco Gobbi, Angelo Michele Carella, Antonella Gozzini, Emilio Usala, Francesco Cavazzini, Paolo Danise, Mario Tiribelli, Gianni Binotto, Patrizia Pregno, Monica Bocchia, Gianluca Gaïdano, Monica Crugnola, Massimiliano Bonifacio, Paolo Avanzini, Francesca Celesti, Anna Guella, Bruno Martino, Mario Annunziata, Luigiana Luciano, Fabio Stagno, Daniele Vallisa, E. Pungolino, Alessandra Iurlo, Alessandro Rambaldi, Ida Nardiello, Esther Orlandi, Carlo Gambacorti‐Passerini, Giuliana Alimena,

Lymphoma Diagnosis and Treatment

Therapeutic approach for chronic myeloid leukemia (CML) patients has undergone a revolutionary change with the introduction of tyrosine kinase inhibitors, which improved overall survival and quality of life. Optimal therapy adherence has become of paramount importance to maximize the benefits in the long-term outcome. Several evidences have been reported that personal factors, such as social support, psychological and subjective perceptions about the drug used and the future, could influence adherence. We here report the results of a questionnaire specifically designed to evaluate factors influencing adherence and perceptions about the future, distributed to patients during regional Italian meetings. Overall, 1133 patients compiled the questionnaire: median age was 57 years. High rate of adherence was reported, but 42% of interviewed patients admitted that they had occasionally postponed a dose and 58% had discontinued therapy mainly for forgetfulness. The majority of patients discussed with personal physician about the importance of adherence and received sufficient information about illness and treatment, but would like to have discussed more about discomfort, anxiety and fear of the future. Summarizing personal drug compliance and estimating how many days a month, on average, the patients did not take the drug, the majority answered that it was less than 3 days (55%) and only a minority (4%) admitted that it was more than 7 days. Interviewed about discontinuation, 49% of patients answered that wouldn’t interrupt because of fear of losing all the results achieved so far. This study suggests a higher level of satisfaction with more information received but the need of improving communication about possible future treatment free remission.